New Treatments and Clinical Trials for Parkinson’s Disease: Check What Is Being Studied Before Deciding Whether to Seek a Consultation

EastMedGo Nov 6, 2026

When you see claims about a “new drug,” “cell transplant,” or “latest brain stimulator,” first write down the product name and where it is offered. Ask the research team: Which symptoms is it intended to improve? Who was studied to produce the evidence? Is it an approved treatment or research at this location? Once the answers and your routine care plan are clear, consider whether to travel or undergo screening.

Key points

Improved movement, less daily “off” time, and slower disease progression are different outcomes. An improvement on a single rating scale or scan cannot, by itself, prove that the course of the disease has changed.
Approval applies within the jurisdiction that granted it. A study registration, receipt of your records, or passing prescreening does not mean that a treatment is approved, that a study is recruiting, or that enrollment is guaranteed.
Do not stop medication or adjust a device yourself to meet presumed requirements. Seek local medical care first for serious new problems. Research consultations and existing care can be arranged at the same time.

Clarify What You Hope to Improve

Write down one specific goal, such as “spend less time unable to walk before my next dose” or “eat more safely.” Studies may measure movement scores, “on” and “off” time in patient diaries, quality of life, imaging findings, or biomarkers. Ask the doctor: What is the study’s primary endpoint—the main outcome it measures? Is there a control group? How long were participants followed? What does the change mean for daily life? A change on a scan does not automatically mean an improvement that patients can feel. Findings in subgroups identified only after the study need further confirmation.

Symptom improvement does not mean that slowing of disease progression has been proven. Different symptoms may also need different care: even if movement improves, swallowing, thinking and memory, sleep, and falls still need separate assessment.[1][2]

What These Developments Actually Show

Tavapadon (JUVMO): The US FDA has approved it to treat Parkinson’s disease in adults. The TEMPO-1 randomized trial compared the drug with placebo in 529 people with early Parkinson’s disease. At 26 weeks, the drug group had greater improvement in a combined score for movement and daily activities. Participants had early disease, so the results cannot be applied directly to everyone. Common adverse effects in the drug group included nausea, headache, and dizziness, and a higher proportion stopped treatment because of adverse events than in the placebo group. The US prescribing information also includes studies of use with levodopa. This drug treats symptoms; the evidence above does not prove that it slows disease progression. The prescribing information warns about risks including low blood pressure, impulse control problems, hallucinations, and involuntary movements. Drug interactions also need to be checked.[3][4] US approval does not mean that it is approved or available in China. Ask the hospital to verify this before your consultation.

Prasinezumab: In the phase 2 randomized PADOVA study involving people with early Parkinson’s disease receiving stable symptom treatment, the primary endpoint did not meet the statistical requirement. Prespecified exploratory analyses provided leads for further research. They cannot establish that the treatment has been proven to slow disease progression, and subgroup results cannot guarantee an individual benefit. Serious adverse events were reported in both study groups. During a consultation, ask the team to explain infusion risks and how they are managed.[5]

Exenatide: The primary movement endpoint in a 2025 phase 3 study did not show the expected benefit. In 2026, The Lancet published an expression of concern about the paper. Read both the paper and the notice; the notice does not mean that the opposite finding on effectiveness has been proven.[6] If you use a related medicine for diabetes or another reason, discuss it with the prescribing doctor first. Do not stop it yourself or change its use to treat Parkinson’s disease.

Cell transplantation: Japan has granted conditional, time-limited approval to the specific product AMCHEPRY (raguneprocel) to improve movement symptoms in people with Parkinson’s disease whose existing drug treatment is not sufficiently effective. Confirm the eligibility conditions and actual availability with the treating institution in Japan. This approval applies to a specific product and pathway in Japan. In Kyoto University’s phase 1/2 study, 7 people received transplants of cells derived from induced pluripotent stem cells (iPS cells) into the brain. The study mainly assessed safety, with 24 months of follow-up. It had no control group and few participants, so it cannot establish each person’s benefit or rule out longer-term risks. Check the arrangements for surgery, immune suppression, and follow-up.[7][8]

A separate phase 1 study of bemdaneprocel used cells derived from human embryonic stem cells. Twelve people received transplants into the brain, mainly to assess safety; a seizure related to surgery was reported. The cell sources and products in these two studies differ. Their results cannot be used interchangeably, and Japan’s approval cannot be used to endorse “stem cell infusions” elsewhere.[9] Ask about the exact product, cell source, administration site, study or approval documents, management of the immune response, long-term monitoring, and the team’s ability to treat complications.

Adaptive DBS (deep brain stimulation): US FDA approval covers optional programming features and eligible patient groups for a specific system. These features are not available on every implanted device, and this approval does not establish that the same features or indications are available in China.[10] Ask the team to check the device hardware, software, programming capabilities, and maintenance after you return home. Whether surgery is suitable requires specialist assessment.

How to Check a Study and Your Eligibility

Find the study through a trial registry or the hospital’s research office. Record its name, registration number, sponsor, hospital, and specific research team. Send the registry page to the actual study center and ask whether that hospital site is currently open for screening and accepts patients from other countries. Any recruitment status shown in a registry or on a webpage needs confirmation from the center.[11]
Read both the inclusion and exclusion criteria. Prepare your diagnostic history and the names, formulations, doses, and timing of current and past medications. Record times when medication works well and when you have difficulties, involuntary movements, falls, and changes in thinking, memory, or swallowing. Bring relevant scans, your surgical history, your DBS device card, and programming records. Provide complete information about other conditions and medicines; do not leave out medical history that seems to make you ineligible.
Some studies require specific genetic findings or biomarkers. Ask the team to explain why testing is needed, what the results mean, possible implications for family members, and privacy arrangements. A matching test result is only one part of screening. Ask a qualified professional to explain results of uncertain significance.
Ask the center to state in writing whether it is waiting for records, conducting prescreening or formal screening, or has already enrolled you. Ask what happens next, who is responsible, and when you will receive a reply. Formal screening may still find that you are ineligible. Agree with your current doctor in advance on treatment while you wait and if you are not enrolled.

Ask About Risks, Costs, and Withdrawal Before Deciding

Before signing, request informed consent materials you can understand. Allow time to discuss them with the study doctor, and consider bringing someone you trust. Ask which groups you might be assigned to, whether there is a placebo or sham procedure, which medicines and tests need to be adjusted, what options are available outside the study, what risks are known or unknown, and whom to contact day or night if an adverse event occurs. A study may require follow-up visits over a long period. Completed procedures, such as surgery or transplantation, cannot be undone by withdrawing.

Ask how routine treatment will continue after withdrawal, how data already collected will be handled, and which safety follow-up remains medically meaningful. For people whose ability to make decisions may change, ask the research team and ethics committee to explain how they assess the person’s understanding and ability to consent, when a legally authorized representative is required, and how the person’s wishes will be respected. Do not assume that a family member’s signature can replace every requirement.[12]

Article 8 of China’s Regulations for the Implementation of the Drug Administration Law states that sponsors and trial institutions must not charge participants fees related to a drug clinical trial.[13] First ask the center to explain which pathway the project falls under, then request an itemized written cost plan covering study-related items, routine medical care, travel and accommodation, translation and interpreting, complications, and treatment after withdrawal. The center and relevant authorities should confirm who is responsible for specific costs and which rules apply to other types of research. If promotional material makes a vague demand for advance payment or cannot provide information identifying the project, pause and verify it.

How to Arrange Ongoing Care Before Coming to China

Confirm with your current neurologist and the research team how you will obtain and take medication on time during travel, how to handle time zone changes, whether screening requires a supervised assessment, and who will take over your care if treatment is delayed or you are ineligible. Do not stop medication, reduce doses, or change device settings yourself to create an “off” period. If you have difficulty swallowing, are vomiting, are hospitalized and instructed not to eat or drink, or cannot take medication on time, contact the local treating team promptly. Tell them the medicine names, usual dosing times, and any missed doses, and ask them to contact a Parkinson’s specialist to arrange a safety assessment. If you cannot swallow safely, or cannot take medication on time and cannot promptly obtain medical advice, go to the nearest emergency department. If you are choking or having difficulty breathing, call local emergency services immediately. Do not crush tablets, switch medicines, or devise an alternative way to take medication yourself.[2][15]

Confirm arrangements for a caregiver, mobility and swallowing support, the number of hospital visits, interpreting, remote and in-person follow-up, the doctor who will take over after you return home, emergency contacts, and transfer of medical records. If you have DBS, bring the model details, device card, and latest programming records. Ask in advance whether the team taking over your care has compatible equipment and relevant experience. For emergencies such as sudden confusion, difficulty breathing, or new weakness on one side, call local emergency services or go to an emergency department immediately. Do not wait for the research center to reply.[14]

Frequently Asked Questions

If a study has a trial number, can I book treatment?

A trial number helps you find the study, but it does not prove that the local center is currently recruiting or that you are eligible. Ask the center to confirm the hospital site, research team, screening status, and next step.

Do fluctuations in medication benefit mean I must join a trial or have surgery?

No. First ask a movement disorders specialist to review your symptoms and current treatment. Then compare the goals, risks, and follow-up demands of routine care and research.[2]

If a study reports improved imaging findings, does that mean the disease will worsen more slowly?

You cannot draw that conclusion directly. Ask the research team how the imaging measure relates to patients’ functioning, and whether there are reliable clinical outcomes and a sufficiently long observation period.

If a drug is approved in the United States, can I buy it in China?

US approval alone cannot establish this. Ask the treating hospital and check local regulatory information to verify the specific product, approved indications, and availability.

Do cell studies always require brain surgery?

The two studies described here used transplantation into the brain. Other projects may involve different cells, administration routes, and risks. Ask the project team for details; do not treat different projects as the same treatment.

Can I withdraw after signing the consent form?

You can ask the research team to withdraw. First clarify subsequent safety follow-up, continuation of routine treatment, and handling of your data. Procedures already completed, such as surgery, cannot be undone.[12]

If my test results meet the requirements, am I guaranteed enrollment?

No. Your diagnosis, medications, overall condition, and all other criteria still need to be checked, and the research team must complete formal screening.

Can a family member whose memory is getting worse still make their own decisions?

Memory changes alone cannot replace an individual assessment. Ask the research team to communicate in a way the patient can understand, assess their understanding of the specific decision, and explain what support or legally authorized representation is needed.[12]

Sources

The following are the original studies and official materials supporting the statements above. Date checked: 2026-11-06. Specific projects and availability should be checked again before taking action.